$NVRO Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in NEVRO CORP.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in NEVRO CORP. Get notifications about new insider transactions in NEVRO CORP for free.
Page: < prev 1 2 3 4 5 6 6 next >
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Nov 03 2017 | NVRO | NEVRO CORP | Christoforou Christofer | VP, Research & Deve ... | Payment of Exercise | F | 88.99 | 234 | 20,824 | 11,327 | 11.6 K to 11.3 K (-2.02 %) |
Nov 03 2017 | NVRO | NEVRO CORP | Alleavitch Doug | VP, Quality | Payment of Exercise | F | 88.99 | 313 | 27,854 | 9,266 | 9.6 K to 9.3 K (-3.27 %) |
Oct 10 2017 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Sell | S | 93.50 | 5,000 | 467,500 | 427,313 | 432.3 K to 427.3 K (-1.16 %) |
Sep 28 2017 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Sell | S | 91.50 | 5,000 | 457,500 | 432,313 | 437.3 K to 432.3 K (-1.14 %) |
Sep 18 2017 | NVRO | NEVRO CORP | JAEGER WILFRED E | Director | Sell | S | 90.31 | 286 | 25,829 | 20,764 | 21.1 K to 20.8 K (-1.36 %) |
Sep 18 2017 | NVRO | NEVRO CORP | JAEGER WILFRED E | Director | Sell | S | 90.31 | 12,935 | 1,168,162 | 940,387 | 953.3 K to 940.4 K (-1.36 %) |
Sep 18 2017 | NVRO | NEVRO CORP | JAEGER WILFRED E | Director | Sell | S | 89.72 | 70 | 6,280 | 21,050 | 21.1 K to 21.1 K (-0.33 %) |
Sep 18 2017 | NVRO | NEVRO CORP | JAEGER WILFRED E | Director | Sell | S | 89.72 | 3,176 | 284,935 | 953,322 | 956.5 K to 953.3 K (-0.33 %) |
Sep 15 2017 | NVRO | NEVRO CORP | Behbahani Ali | Director | Buy | J | 0.00 | 8 | 0 | 1,605 | 1.6 K to 1.6 K (+0.50 %) |
Sep 15 2017 | NVRO | NEVRO CORP | Behbahani Ali | Director | Buy | J | 0.00 | 32 | 0 | 1,597 | 1.6 K to 1.6 K (+2.04 %) |
Sep 14 2017 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Sell | S | 89.50 | 5,000 | 447,500 | 42,554 | 47.6 K to 42.6 K (-10.51 %) |
Sep 13 2017 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Sell | S | 88.39 | 4,350 | 384,494 | 47,554 | 51.9 K to 47.6 K (-8.38 %) |
Sep 13 2017 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Sell | S | 87.59 | 20,650 | 1,808,705 | 51,904 | 72.6 K to 51.9 K (-28.46 %) |
Aug 24 2017 | NVRO | NEVRO CORP | JAEGER WILFRED E | Director | Sell | S | 87.00 | 158 | 13,746 | 21,120 | 21.3 K to 21.1 K (-0.74 %) |
Aug 24 2017 | NVRO | NEVRO CORP | JAEGER WILFRED E | Director | Sell | S | 87.00 | 7,156 | 622,572 | 956,498 | 963.7 K to 956.5 K (-0.74 %) |
Aug 24 2017 | NVRO | NEVRO CORP | JAEGER WILFRED E | Director | Sell | S | 87.01 | 112 | 9,745 | 21,278 | 21.4 K to 21.3 K (-0.52 %) |
Aug 24 2017 | NVRO | NEVRO CORP | JAEGER WILFRED E | Director | Sell | S | 87.01 | 5,094 | 443,237 | 963,654 | 968.7 K to 963.7 K (-0.53 %) |
Aug 24 2017 | NVRO | NEVRO CORP | JAEGER WILFRED E | Director | Sell | S | 86.48 | 432 | 37,360 | 21,390 | 21.8 K to 21.4 K (-1.98 %) |
Aug 24 2017 | NVRO | NEVRO CORP | JAEGER WILFRED E | Director | Sell | S | 86.48 | 19,568 | 1,692,252 | 968,748 | 988.3 K to 968.7 K (-1.98 %) |
Aug 24 2017 | NVRO | NEVRO CORP | JAEGER WILFRED E | Director | Sell | S | 85.17 | 432 | 36,795 | 21,822 | 22.3 K to 21.8 K (-1.94 %) |
Aug 24 2017 | NVRO | NEVRO CORP | JAEGER WILFRED E | Director | Sell | S | 85.17 | 19,568 | 1,666,669 | 988,316 | 1 M to 988.3 K (-1.94 %) |
Aug 21 2017 | NVRO | NEVRO CORP | JAEGER WILFRED E | Director | Sell | S | 84.44 | 540 | 45,600 | 22,254 | 22.8 K to 22.3 K (-2.37 %) |
Aug 21 2017 | NVRO | NEVRO CORP | JAEGER WILFRED E | Director | Sell | S | 84.44 | 24,460 | 2,065,512 | 1,007,884 | 1 M to 1 M (-2.37 %) |
Aug 21 2017 | NVRO | NEVRO CORP | JAEGER WILFRED E | Director | Sell | S | 84.02 | 331 | 27,810 | 22,794 | 23.1 K to 22.8 K (-1.43 %) |
Aug 21 2017 | NVRO | NEVRO CORP | JAEGER WILFRED E | Director | Sell | S | 84.02 | 15,012 | 1,261,290 | 1,032,344 | 1 M to 1 M (-1.43 %) |
Aug 16 2017 | NVRO | NEVRO CORP | JAEGER WILFRED E | Director | Sell | S | 84.04 | 236 | 19,834 | 23,125 | 23.4 K to 23.1 K (-1.01 %) |
Aug 16 2017 | NVRO | NEVRO CORP | JAEGER WILFRED E | Director | Sell | S | 84.04 | 10,701 | 899,329 | 1,047,356 | 1.1 M to 1 M (-1.01 %) |
Aug 16 2017 | NVRO | NEVRO CORP | JAEGER WILFRED E | Director | Sell | S | 82.75 | 299 | 24,743 | 23,361 | 23.7 K to 23.4 K (-1.26 %) |
Aug 16 2017 | NVRO | NEVRO CORP | JAEGER WILFRED E | Director | Sell | S | 82.75 | 13,501 | 1,117,227 | 1,058,057 | 1.1 M to 1.1 M (-1.26 %) |
Aug 16 2017 | NVRO | NEVRO CORP | JAEGER WILFRED E | Director | Sell | S | 82.54 | 641 | 52,905 | 23,660 | 24.3 K to 23.7 K (-2.64 %) |
Aug 16 2017 | NVRO | NEVRO CORP | JAEGER WILFRED E | Director | Sell | S | 82.54 | 29,024 | 2,395,519 | 1,071,558 | 1.1 M to 1.1 M (-2.64 %) |
Aug 16 2017 | NVRO | NEVRO CORP | JAEGER WILFRED E | Director | Sell | S | 82.40 | 546 | 44,991 | 24,301 | 24.8 K to 24.3 K (-2.20 %) |
Aug 16 2017 | NVRO | NEVRO CORP | JAEGER WILFRED E | Director | Sell | S | 82.40 | 24,709 | 2,036,027 | 1,100,582 | 1.1 M to 1.1 M (-2.20 %) |
Aug 16 2017 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Option Exercise | M | 18.00 | 204 | 3,672 | 42,463 | |
Aug 16 2017 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Option Exercise | M | 3.60 | 6,144 | 22,118 | 36,286 | |
Aug 16 2017 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Option Exercise | M | 3.60 | 652 | 2,347 | 43,894 | |
Aug 16 2017 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Sell | S | 82.31 | 7,000 | 576,192 | 11,833 | 18.8 K to 11.8 K (-37.17 %) |
Aug 16 2017 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Buy | M | 18.00 | 204 | 3,672 | 18,833 | 18.6 K to 18.8 K (+1.10 %) |
Aug 16 2017 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Buy | M | 3.60 | 6,144 | 22,118 | 18,629 | 12.5 K to 18.6 K (+49.21 %) |
Aug 16 2017 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Buy | M | 3.60 | 652 | 2,347 | 12,485 | 11.8 K to 12.5 K (+5.51 %) |
Aug 04 2017 | NVRO | NEVRO CORP | Christoforou Christofer | VP, Research & Deve ... | Payment of Exercise | F | 82.00 | 939 | 76,998 | 11,561 | 12.5 K to 11.6 K (-7.51 %) |
Jun 05 2017 | NVRO | NEVRO CORP | Elghandour Rami | President & CEO | Payment of Exercise | F | 69.74 | 6,231 | 434,550 | 86,916 | 93.1 K to 86.9 K (-6.69 %) |
Jun 05 2017 | NVRO | NEVRO CORP | Elghandour Rami | President & CEO | Payment of Exercise | F | 69.74 | 2,077 | 144,850 | 93,147 | 95.2 K to 93.1 K (-2.18 %) |
May 30 2017 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Option Exercise | A | 74.07 | 3,545 | 262,578 | 3,545 | |
May 30 2017 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Grant | A | 0.00 | 1,518 | 0 | 487,313 | 485.8 K to 487.3 K (+0.31 %) |
May 30 2017 | NVRO | NEVRO CORP | Vale Brad | Director | Option Exercise | A | 74.07 | 3,545 | 262,578 | 3,545 | |
May 30 2017 | NVRO | NEVRO CORP | Vale Brad | Director | Grant | A | 0.00 | 1,518 | 0 | 3,518 | 2 K to 3.5 K (+75.90 %) |
May 30 2017 | NVRO | NEVRO CORP | Behbahani Ali | Director | Option Exercise | A | 74.07 | 3,545 | 262,578 | 3,545 | |
May 30 2017 | NVRO | NEVRO CORP | Behbahani Ali | Director | Grant | A | 0.00 | 1,518 | 0 | 1,565 | 47 to 1.6 K (+3,229.79 %) |
May 30 2017 | NVRO | NEVRO CORP | McCormick Shawn | Director | Option Exercise | A | 74.07 | 3,545 | 262,578 | 3,545 | |
May 30 2017 | NVRO | NEVRO CORP | McCormick Shawn | Director | Grant | A | 0.00 | 1,518 | 0 | 1,518 | 0 to 1.5 K |
May 30 2017 | NVRO | NEVRO CORP | JAEGER WILFRED E | Director | Option Exercise | A | 74.07 | 3,545 | 262,578 | 3,545 | |
May 30 2017 | NVRO | NEVRO CORP | JAEGER WILFRED E | Director | Grant | A | 0.00 | 1,518 | 0 | 1,518 | 0 to 1.5 K |
May 30 2017 | NVRO | NEVRO CORP | Fischer Frank M | Director | Option Exercise | A | 74.07 | 3,545 | 262,578 | 3,545 | |
May 30 2017 | NVRO | NEVRO CORP | Fischer Frank M | Director | Grant | A | 0.00 | 1,518 | 0 | 60,518 | 59 K to 60.5 K (+2.57 %) |
May 30 2017 | NVRO | NEVRO CORP | Earnhardt Lisa D | Director | Option Exercise | A | 74.07 | 3,545 | 262,578 | 3,545 | |
May 30 2017 | NVRO | NEVRO CORP | Earnhardt Lisa D | Director | Grant | A | 0.00 | 1,518 | 0 | 1,518 | 0 to 1.5 K |
May 16 2017 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Option Exercise | M | 3.60 | 7,500 | 27,000 | 44,546 | |
May 16 2017 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Sell | S | 76.40 | 1,306 | 99,782 | 11,833 | 13.1 K to 11.8 K (-9.94 %) |
May 16 2017 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Sell | S | 75.55 | 2,698 | 203,826 | 13,139 | 15.8 K to 13.1 K (-17.04 %) |
May 16 2017 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Sell | S | 74.69 | 3,496 | 261,126 | 15,837 | 19.3 K to 15.8 K (-18.08 %) |
May 16 2017 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Buy | M | 3.60 | 7,500 | 27,000 | 19,333 | 11.8 K to 19.3 K (+63.38 %) |
May 11 2017 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Option Exercise | M | 1.44 | 5,000 | 7,200 | 22,404 | |
May 11 2017 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Buy | M | 1.44 | 5,000 | 7,200 | 11,833 | 6.8 K to 11.8 K (+73.17 %) |
May 03 2017 | NVRO | NEVRO CORP | Elghandour Rami | President & CEO | Option Exercise | M | 3.60 | 10,000 | 36,000 | 65,051 | |
May 03 2017 | NVRO | NEVRO CORP | Elghandour Rami | President & CEO | Sell | S | 95.03 | 10,000 | 950,302 | 95,224 | 105.2 K to 95.2 K (-9.50 %) |
May 03 2017 | NVRO | NEVRO CORP | Elghandour Rami | President & CEO | Buy | M | 3.60 | 10,000 | 36,000 | 105,224 | 95.2 K to 105.2 K (+10.50 %) |
May 03 2017 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Sell | S | 97.00 | 16,000 | 1,552,000 | 485,795 | 501.8 K to 485.8 K (-3.19 %) |
May 03 2017 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Sell | S | 95.00 | 13,800 | 1,311,000 | 501,795 | 515.6 K to 501.8 K (-2.68 %) |
Apr 07 2017 | NVRO | NEVRO CORP | Schmitz Patrick | Vice President, Ope ... | Payment of Exercise | F | 92.70 | 423 | 39,212 | 7,410 | 7.8 K to 7.4 K (-5.40 %) |
Apr 05 2017 | NVRO | NEVRO CORP | Enxing Michael | VP of Sales | Option Exercise | M | 3.60 | 1,500 | 5,400 | 37,108 | |
Apr 05 2017 | NVRO | NEVRO CORP | Enxing Michael | VP of Sales | Sell | S | 94.48 | 300 | 28,343 | 40,463 | 40.8 K to 40.5 K (-0.74 %) |
Apr 05 2017 | NVRO | NEVRO CORP | Enxing Michael | VP of Sales | Sell | S | 93.29 | 1,200 | 111,947 | 40,763 | 42 K to 40.8 K (-2.86 %) |
Apr 05 2017 | NVRO | NEVRO CORP | Enxing Michael | VP of Sales | Buy | M | 3.60 | 1,500 | 5,400 | 41,963 | 40.5 K to 42 K (+3.71 %) |
Apr 05 2017 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Sell | S | 95.17 | 300 | 28,552 | 515,595 | 515.9 K to 515.6 K (-0.06 %) |
Apr 05 2017 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Sell | S | 94.47 | 1,900 | 179,493 | 515,895 | 517.8 K to 515.9 K (-0.37 %) |
Apr 05 2017 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Sell | S | 93.26 | 20,000 | 1,865,134 | 517,795 | 537.8 K to 517.8 K (-3.72 %) |
Apr 05 2017 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Sell | S | 95.04 | 14,297 | 1,358,791 | 6,833 | 21.1 K to 6.8 K (-67.66 %) |
Apr 05 2017 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Sell | S | 94.32 | 9,166 | 864,569 | 21,130 | 30.3 K to 21.1 K (-30.25 %) |
Apr 05 2017 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Sell | S | 93.39 | 6,537 | 610,468 | 30,296 | 36.8 K to 30.3 K (-17.75 %) |
Mar 30 2017 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Option Exercise | M | 18.00 | 691 | 12,438 | 83,922 | |
Mar 30 2017 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Option Exercise | M | 3.60 | 12,929 | 46,544 | 41,572 | |
Mar 30 2017 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Buy | M | 18.00 | 691 | 12,438 | 537,795 | 537.1 K to 537.8 K (+0.13 %) |
Mar 30 2017 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Buy | M | 3.60 | 12,929 | 46,544 | 537,104 | 524.2 K to 537.1 K (+2.47 %) |
Mar 08 2017 | NVRO | NEVRO CORP | Enxing Michael | VP of Sales | Option Exercise | M | 3.60 | 1,500 | 5,400 | 38,608 | |
Mar 08 2017 | NVRO | NEVRO CORP | Enxing Michael | VP of Sales | Sell | S | 92.85 | 100 | 9,285 | 40,463 | 40.6 K to 40.5 K (-0.25 %) |
Mar 08 2017 | NVRO | NEVRO CORP | Enxing Michael | VP of Sales | Sell | S | 92.35 | 600 | 55,412 | 40,563 | 41.2 K to 40.6 K (-1.46 %) |
Mar 08 2017 | NVRO | NEVRO CORP | Enxing Michael | VP of Sales | Sell | S | 90.90 | 800 | 72,723 | 41,163 | 42 K to 41.2 K (-1.91 %) |
Mar 08 2017 | NVRO | NEVRO CORP | Enxing Michael | VP of Sales | Buy | M | 3.60 | 1,500 | 5,400 | 41,963 | 40.5 K to 42 K (+3.71 %) |
Mar 08 2017 | NVRO | NEVRO CORP | Enxing Michael | VP of Sales | Sell | S | 90.99 | 37,000 | 3,366,593 | 40,463 | 77.5 K to 40.5 K (-47.76 %) |
Mar 03 2017 | NVRO | NEVRO CORP | JAEGER WILFRED E | Director | Sell | S | 95.00 | 16 | 1,520 | 24,847 | 24.9 K to 24.8 K (-0.06 %) |
Mar 03 2017 | NVRO | NEVRO CORP | JAEGER WILFRED E | Director | Sell | S | 95.00 | 703 | 66,785 | 1,125,291 | 1.1 M to 1.1 M (-0.06 %) |
Mar 03 2017 | NVRO | NEVRO CORP | JAEGER WILFRED E | Director | Sell | S | 95.00 | 6 | 570 | 24,863 | 24.9 K to 24.9 K (-0.02 %) |
Mar 03 2017 | NVRO | NEVRO CORP | JAEGER WILFRED E | Director | Sell | S | 95.00 | 294 | 27,930 | 1,125,994 | 1.1 M to 1.1 M (-0.03 %) |
Mar 03 2017 | NVRO | NEVRO CORP | JAEGER WILFRED E | Director | Sell | S | 95.03 | 928 | 88,191 | 24,869 | 25.8 K to 24.9 K (-3.60 %) |
Mar 03 2017 | NVRO | NEVRO CORP | JAEGER WILFRED E | Director | Sell | S | 95.03 | 42,033 | 3,994,535 | 1,126,288 | 1.2 M to 1.1 M (-3.60 %) |
Feb 23 2017 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Sell | S | 97.30 | 4,255 | 414,012 | 0 | 4.3 K to 0 (-100.00 %) |
Feb 23 2017 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Sell | S | 97.30 | 1,745 | 169,789 | 524,175 | 525.9 K to 524.2 K (-0.33 %) |
Feb 08 2017 | NVRO | NEVRO CORP | Enxing Michael | VP of Sales | Option Exercise | M | 3.60 | 1,500 | 5,400 | 40,108 | |
Feb 08 2017 | NVRO | NEVRO CORP | Enxing Michael | VP of Sales | Sell | S | 93.27 | 1,500 | 139,908 | 77,463 | 79 K to 77.5 K (-1.90 %) |
Feb 08 2017 | NVRO | NEVRO CORP | Enxing Michael | VP of Sales | Buy | M | 3.60 | 1,500 | 5,400 | 78,963 | 77.5 K to 79 K (+1.94 %) |
Jan 30 2017 | NVRO | NEVRO CORP | Enxing Michael | VP of Sales | Option Exercise | M | 3.60 | 37,000 | 133,200 | 41,608 | |
Jan 30 2017 | NVRO | NEVRO CORP | Enxing Michael | VP of Sales | Buy | M | 3.60 | 37,000 | 133,200 | 77,463 | 40.5 K to 77.5 K (+91.44 %) |
Jan 05 2017 | NVRO | NEVRO CORP | Elghandour Rami | President & CEO | Option Exercise | A | 75.17 | 124,175 | 9,334,235 | 124,175 | |
Jan 05 2017 | NVRO | NEVRO CORP | Elghandour Rami | President & CEO | Grant | A | 0.00 | 31,044 | 0 | 95,224 | 64.2 K to 95.2 K (+48.37 %) |
Jan 05 2017 | NVRO | NEVRO CORP | Enxing Michael | VP of Sales | Option Exercise | M | 3.60 | 1,500 | 5,400 | 78,608 | |
Jan 05 2017 | NVRO | NEVRO CORP | Enxing Michael | VP of Sales | Sell | S | 76.97 | 400 | 30,787 | 40,463 | 40.9 K to 40.5 K (-0.98 %) |
Jan 05 2017 | NVRO | NEVRO CORP | Enxing Michael | VP of Sales | Sell | S | 76.12 | 500 | 38,059 | 40,863 | 41.4 K to 40.9 K (-1.21 %) |
Jan 05 2017 | NVRO | NEVRO CORP | Enxing Michael | VP of Sales | Sell | S | 74.96 | 600 | 44,978 | 41,363 | 42 K to 41.4 K (-1.43 %) |
Jan 05 2017 | NVRO | NEVRO CORP | Enxing Michael | VP of Sales | Buy | M | 3.60 | 1,500 | 5,400 | 41,963 | 40.5 K to 42 K (+3.71 %) |
Dec 07 2016 | NVRO | NEVRO CORP | Enxing Michael | VP of Sales | Option Exercise | M | 3.60 | 1,500 | 5,400 | 80,108 | |
Dec 07 2016 | NVRO | NEVRO CORP | Enxing Michael | VP of Sales | Sell | S | 76.38 | 1,500 | 114,573 | 40,463 | 42 K to 40.5 K (-3.57 %) |
Dec 07 2016 | NVRO | NEVRO CORP | Enxing Michael | VP of Sales | Buy | M | 3.60 | 1,500 | 5,400 | 41,963 | 40.5 K to 42 K (+3.71 %) |
Dec 02 2016 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Option Exercise | M | 3.60 | 10,000 | 36,000 | 54,501 | |
Dec 02 2016 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Buy | M | 3.60 | 10,000 | 36,000 | 525,920 | 515.9 K to 525.9 K (+1.94 %) |
Nov 18 2016 | NVRO | NEVRO CORP | Schmitz Patrick | Vice President, Ope ... | Option Exercise | A | 87.62 | 13,333 | 1,168,237 | 13,333 | |
Nov 18 2016 | NVRO | NEVRO CORP | Schmitz Patrick | Vice President, Ope ... | Grant | A | 0.00 | 3,333 | 0 | 7,833 | 4.5 K to 7.8 K (+74.07 %) |
Nov 18 2016 | NVRO | NEVRO CORP | Enxing Michael | VP of Sales | Option Exercise | A | 87.62 | 10,000 | 876,200 | 10,000 | |
Nov 18 2016 | NVRO | NEVRO CORP | Enxing Michael | VP of Sales | Grant | A | 0.00 | 2,500 | 0 | 40,463 | 38 K to 40.5 K (+6.59 %) |
Nov 18 2016 | NVRO | NEVRO CORP | Alleavitch Doug | VP, Quality | Option Exercise | A | 87.62 | 13,333 | 1,168,237 | 13,333 | |
Nov 18 2016 | NVRO | NEVRO CORP | Alleavitch Doug | VP, Quality | Grant | A | 0.00 | 3,333 | 0 | 9,294 | 6 K to 9.3 K (+55.91 %) |
Nov 18 2016 | NVRO | NEVRO CORP | Christoforou Christofer | VP, Research & Deve ... | Option Exercise | A | 87.62 | 10,000 | 876,200 | 10,000 | |
Nov 18 2016 | NVRO | NEVRO CORP | Christoforou Christofer | VP, Research & Deve ... | Grant | A | 0.00 | 2,500 | 0 | 12,500 | 10 K to 12.5 K (+25.00 %) |
Nov 18 2016 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Option Exercise | A | 87.62 | 27,333 | 2,394,917 | 27,333 | |
Nov 18 2016 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Grant | A | 0.00 | 6,833 | 0 | 36,833 | 30 K to 36.8 K (+22.78 %) |
Nov 16 2016 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Option Exercise | M | 18.00 | 4,185 | 75,330 | 42,667 | |
Nov 16 2016 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Option Exercise | M | 3.60 | 3,315 | 11,934 | 59,546 | |
Nov 16 2016 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Sell | S | 87.55 | 2,906 | 254,416 | 30,000 | 32.9 K to 30 K (-8.83 %) |
Nov 16 2016 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Sell | S | 86.75 | 3,734 | 323,942 | 32,906 | 36.6 K to 32.9 K (-10.19 %) |
Nov 16 2016 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Sell | S | 85.70 | 660 | 56,563 | 36,640 | 37.3 K to 36.6 K (-1.77 %) |
Nov 16 2016 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Sell | S | 84.17 | 200 | 16,833 | 37,300 | 37.5 K to 37.3 K (-0.53 %) |
Nov 16 2016 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Buy | M | 18.00 | 4,185 | 75,330 | 37,500 | 33.3 K to 37.5 K (+12.56 %) |
Nov 16 2016 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Buy | M | 3.60 | 3,315 | 11,934 | 33,315 | 30 K to 33.3 K (+11.05 %) |
Nov 15 2016 | NVRO | NEVRO CORP | Behbahani Ali | Director | Buy | J | 0.00 | 3 | 0 | 47 | 44 to 47 (+6.82 %) |
Nov 15 2016 | NVRO | NEVRO CORP | Behbahani Ali | Director | Buy | J | 0.00 | 19 | 0 | 44 | 25 to 44 (+76.00 %) |
Nov 10 2016 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Option Exercise | M | 3.60 | 30,000 | 108,000 | 64,501 | |
Nov 10 2016 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Buy | M | 3.60 | 30,000 | 108,000 | 515,920 | 485.9 K to 515.9 K (+6.17 %) |
Nov 08 2016 | NVRO | NEVRO CORP | Enxing Michael | VP of Sales | Option Exercise | M | 3.60 | 1,500 | 5,400 | 81,608 | |
Nov 08 2016 | NVRO | NEVRO CORP | Enxing Michael | VP of Sales | Sell | S | 88.68 | 19 | 1,685 | 37,963 | 38 K to 38 K (-0.05 %) |
Nov 08 2016 | NVRO | NEVRO CORP | Enxing Michael | VP of Sales | Sell | S | 87.93 | 550 | 48,362 | 37,982 | 38.5 K to 38 K (-1.43 %) |
Nov 08 2016 | NVRO | NEVRO CORP | Enxing Michael | VP of Sales | Sell | S | 86.29 | 300 | 25,887 | 38,532 | 38.8 K to 38.5 K (-0.77 %) |
Nov 08 2016 | NVRO | NEVRO CORP | Enxing Michael | VP of Sales | Sell | S | 85.34 | 365 | 31,149 | 38,832 | 39.2 K to 38.8 K (-0.93 %) |
Nov 08 2016 | NVRO | NEVRO CORP | Enxing Michael | VP of Sales | Sell | S | 83.75 | 266 | 22,278 | 39,197 | 39.5 K to 39.2 K (-0.67 %) |
Nov 08 2016 | NVRO | NEVRO CORP | Enxing Michael | VP of Sales | Buy | M | 3.60 | 1,500 | 5,400 | 39,463 | 38 K to 39.5 K (+3.95 %) |
Oct 12 2016 | NVRO | NEVRO CORP | Elghandour Rami | President & CEO | Option Exercise | M | 3.60 | 3,000 | 10,800 | 75,051 | |
Oct 12 2016 | NVRO | NEVRO CORP | Elghandour Rami | President & CEO | Sell | S | 100.00 | 3,000 | 300,000 | 64,180 | 67.2 K to 64.2 K (-4.47 %) |
Oct 12 2016 | NVRO | NEVRO CORP | Elghandour Rami | President & CEO | Buy | M | 3.60 | 3,000 | 10,800 | 67,180 | 64.2 K to 67.2 K (+4.67 %) |
Oct 06 2016 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Option Exercise | M | 63.23 | 18,750 | 1,185,563 | 81,250 | |
Oct 06 2016 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Option Exercise | M | 18.00 | 27,754 | 499,572 | 84,613 | |
Oct 06 2016 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Option Exercise | M | 18.00 | 28,918 | 520,524 | 112,367 |